Result Update

Bajaj Finance



Your success is our success

Refer to important disclosures at the end of this report

Returning to normalcy but uncertainties do exist

Rating HOLD (■) Upside 11.0 %

- BAF reported PAT of Rs13.5bn (+42% yoy, +17.5% qoq) in Q4FY21, aided by solid growth momentum across lending segments (except auto). However, recent lockdowns amid the second wave of Covid-19 pose a challenge for BAF due to historically loaded AUM growth in Q1 (~35-40% of full year AUM) and dependence on discretionary spending.
- Though the sharp surge in collection efficiency is positive, we remain concerned about elevated write-offs (Rs20bn in Q4, Rs23.4bn in Q3) and restructured book (Rs17.4bn) placed under stage 2 assets. We also await more ground level data to ascertain the impact of current lockdowns on collection efficiency.
- In the last quarter, management revealed a business transformation journey by creating seamless credit experience and announcing an integrated payment solution. We believe the move is intended to increase the wallet share from the existing customers. Since the process is due in Jul-Aug'21, we await more clarity over the same.
- Although we moderate our AUM growth estimates to 25%/28% for FY22/23 from 28%/30% earlier due to current lockdowns, management's stance of open for all businesses (against shut down for months last year) provides some comfort. We introduce FY24 estimates. Maintain Hold (EW in EAP) with a TP of Rs5400 (~6.5x FY23E ABV).
- Key things to watch out for: 1) possible stress in the loan book; 2) impact on growth during lockdowns and 3) BAF's transformation journey.

Normalcy visible in Q4FY21; better collections led to reduction in credit loss: BAF has reported AUM growth of ~3.9% yoy (+6.5% qoq) to Rs1.53tn, mainly attributable to higher growth across segments along with increasing momentum in recoveries. The reported core AUM growth in Q4 was ~Rs95bn (across all products lines, except for Auto) as compared to Rs80bn in Q3. During FY21, the company has done accelerated write-offs at ~Rs35bn of principal outstanding on account of Covid-19-related stress and advancement of its write-off policy. BAF holds a management overlay and macro provision of Rs8.4bn as of Mar'21

New initiatives picking up speed; a journey toward transformation: BAF management has revealed a business transformation journey by creating an omnichannel framework, which will enable customers to move between online to offline and vice versa in a frictionless manner. The company is also in process of launching an integrated payment solution viz. 'Bajaj Pay', comprising of UPI, PPI, EMI card and credit card for its customers.

Outlook and valuation: Although we moderate our AUM growth estimates to 25%/28% for FY22/23 from 28%/30% previously due to current lockdowns, management's stance of open for all businesses (vs. shutdown for months last year) provides some comfort. We introduce FY24 estimates. Maintain Hold (EW in EAP) with a TP of Rs5,400 (~6.5x FY23E ABV).

Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-NBFCs (Page 8)

Financial Snapshot (Consolidated)

FY20	FY21	FY22E	FY23E	FY24E
2,03,277	2,06,843	2,27,264	2,87,774	3,67,213
94,790	78,349	99,401	1,31,805	1,74,587
102.6	72.1	117.8	163.8	220.8
536.6	584.9	683.1	825.6	1,010.9
4.2	2.6	3.7	4.1	4.3
23.3	12.8	18.0	21.2	23.6
47.4	67.5	41.3	29.7	22.0
8.9	8.2	7.0	5.8	4.7
	2,03,277 94,790 102.6 536.6 4.2 23.3 47.4	2,03,277 2,06,843 94,790 78,349 102.6 72.1 536.6 584.9 4.2 2.6 23.3 12.8 47.4 67.5	2,03,277 2,06,843 2,27,264 94,790 78,349 99,401 102.6 72.1 117.8 536.6 584.9 683.1 4.2 2.6 3.7 23.3 12.8 18.0 47.4 67.5 41.3	2,03,277 2,06,843 2,27,264 2,87,774 94,790 78,349 99,401 1,31,805 102.6 72.1 117.8 163.8 536.6 584.9 683.1 825.6 4.2 2.6 3.7 4.1 23.3 12.8 18.0 21.2 47.4 67.5 41.3 29.7

Change in Estimates	
EPS Chg FY22E/FY23E (%)	(6.4)/ (1.2)
Target Price change (%)	-
Target Period (Months)	12
Previous Reco	HOLD
	

Emkay vs Consensus EPS Estimates

	FY22E	FY23E
Emkay	117.8	163.8
Consensus	136.0	176.8
Mean Consensus TP (12	2M)	Rs 5,167
Stock Details		
Bloomberg Code		BAF IN
Face Value (Rs)		2
Shares outstanding (mn)	603
52 Week H/L	5,9	22 / 1,783
M Cap (Rs bn/USD bn)	2,93	32 / 39.27
Daily Avg Volume (nos.))	27,15,773
Daily Avg Turnover (US	\$ mn)	188.8

Shareholding Pattern Mar '21	
Promoters	56.1%
FIIs	24.1%
DIIs	9.1%
Public and Others	10.7%

Price Performance								
(%)	1M	3M	6M	12M				
Absolute	(6)	-	41	138				
Rel to Nifty	(7)	(4)	14	51				

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Jignesh Shial

jignesh.shial@emkayglobal.com +91 22 6624 2468

Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Aman Jain


aman.jain@emkayglobal.com +91 22 6612 1285

Shrishti Jagati

shrishti.jagati@emkayglobal.com +91 22 6624 2485


Story in Charts

Exhibit 1: AUM growth dips yoy, but recovers to 3.9% on qoq basis




Source: Company, Emkay Research

Exhibit 3: Up-fronting of credit costs during FY21




Source: Company, Emkay Research

Exhibit 5: Improving NPAs on strong collection efficiency




Source: Company, Emkay Research. *Proforma NPLs

Exhibit 2: Strong liability franchise (reducing cost of funds) supports NIMs




Source: Company, Emkay Research

Exhibit 4: Share of mortgage portfolio remains stable at 32% of AUM



Source: Company, Emkay Research

Exhibit 6: BAF boasts of a strong, diversified liability franchise



Source: Company, Emkay Research

Exhibit 7: Actual vs. Estimates (Q4FY21)

Rs mn Actual Estim		Estimates	Consensus	% variation		Comments	
K5 IIIII			Consensus				
Net income	46,594	46,015	41,817	1.3%	11.4%	In line with estimates	
PPOP	30,534	30,260	35,039	0.9%	-12.9%	In line with estimates	
PAT	13,466	11,969	13,705	12.5%	-1.7%	Better than expectations due to lower credit cost	

Source: Company, Emkay Research

Exhibit 8: Quarterly financials

Rs mn	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	YoY (%)	QoQ (%)	FY20	FY21	YoY (%)
Total income	46,834	41,521	41,652	42,958	46,594	-0.5%	8.5%	1,69,124	1,72,691	2.1%
Operating expenses	14,515	11,567	11,593	13,896	16,060	10.6%	15.6%	56,608	53,084	-6.2%
Operating profit	32,320	29,954	30,059	29,062	30,534	-5.5%	5.1%	1,12,516	1,19,606	6.3%
Provisions	19,538	16,857	17,004	13,517	12,308	-37.0%	-8.9%	31,295	59,686	90.7%
% of operating profit	60.5%	56.3%	56.6%	46.5%	40.3%			27.8%	49.9%	
Profit before tax	12,782	13,097	13,055	15,545	18,226	42.6%	17.2%	81,221	59,921	-26.2%
Tax	3,301	3,474	3,406	4,085	4,760			20,584	15,724	-23.6%
Tax rate (%)	25.8%	26.5%	26.1%	26.3%	26.1%			25.3%	26.2%	
Profit after tax	9,481	9,623	9,649	11,460	13,466	42.0%	17.5%	60,638	44,196	-27.1%
AUMs	14,71,530	13,80,550	13,70,900	14,35,500	15,29,470	3.9%	6.5%	14,71,530	15,29,470	3.9%
Borrowings	12,98,060	12,11,200	12,49,000	12,41,620	13,16,454	1.4%	6.0%	12,98,060	13,16,454	1.4%

Source: Company, Emkay Research

Exhibit 9: Revision in estimates

Y/e Mar (Rs mn)	FY22E			FY23E			FY24E	
	Earlier	Revised	% change	Earlier	Revised	% change	Introduced	
Net operating income	2,17,274	2,00,026	-7.9%	2,77,550	2,56,335	-7.6%	3,27,922	
PPOP	1,35,422	1,31,017	-3.3%	1,78,438	1,69,231	-5.2%	2,20,518	
PAT	77,265	72,163	-6.6%	1,01,550	1,00,366	-1.2%	1,35,296	
EPS (Rs)	125.8	117.8	-6.4%	165.8	163.8	-1.2%	220.8	
BV (Rs)	711.8	703	-1.2%	848.6	843	-0.7%	1,031	


Source: Company, Emkay Research

Exhibit 10: Key assumptions

(in %)	FY21	FY22E	FY23E	FY24E
AUM growth	3.9%	25.0%	28.0%	30.0%
Borrowings growth	1.4%	29.4%	28.0%	30.0%
Yield on average loans	18.5%	18.2%	18.0%	17.8%
Cost of average int. liabilities	7.2%	7.0%	6.8%	6.7%

Source: Company, Emkay Research

Exhibit 11: The stock currently trades at 6.8x 1-year forward P/B



Source: Company, Emkay Research

Con-Call highlights

- Despite significant disruptions in the second Covid-19 wave, BAF remains open for business across geographies in line with local administration advisories. In the last 7-10 days, the company continued to originate 50-55% of daily volumes in the B2B business, 80-85% in B2C and SME businesses and 40-50% in mortgages.
- Showing the signs of normalization, credit card origination stands at 95%, ecommerce at 84% and auto finance business at 80%. For the rest of the businesses, urban consumption businesses (B2B) were at 105% and rural consumption business (B2B) at 119% of Q4FY20 volume. The company witnessed slow disbursements in urban B2C at 87% of Q4FY20, while Rural B2C was at 115% and Mortgages at 147%.
- Collection efficiency metrics across businesses for stage 2 and OTR accounts came in significantly better compared to past experience.
- The bounce rates of new origination across businesses are in line or better than pre-Covid origination. The current bucket bounce rate across portfolios is close to pre-Covid levels. The current bucket collection efficiencies across all portfolios are better than pre-Covid levels.
- With the improved bounce rate, higher collection efficiency and overlay provisions, BAF is well positioned to sail through any temporary stress related to Covid-19.
- Management expects credit cost of 150-170bps in FY22 after the Covid-19 impact compared to earlier expectation of 150-160bps. It does not carry any baggage of NPAs but in fact carrying excess provisions of 0.55%.
- The company has done accelerated write-offs in Q4 at Rs15.3bn due to Covid-19-related stress and change in write-off policy. Also, it also recorded Rs5bn of additional write-offs on account of the normal business, taking total write-offs to Rs20bn in Q4. BAF holds a management overlay and macro provision of Rs8.4bn as of Mar'21.
- Operating expenses were higher by Rs1.5bn in Q4FY21 vs. Q4FY20 due to higher recovery commission (up by Rs1.4bn in Q4FY21) and employee related cost (up by Rs1.5bn in Q4FY21), partially offset by prudent management of other expenses.
- All the planned business transformation initiatives are going live by Aug-Sep'21. It will help in accelerating market share as the economic momentum accelerates. BAF will continue to originate customers at POS and then engage them and cross-sell products on apps.
- Given the uncertain market conditions, the company has inched up its liquidity buffer to ~12.52% of its total borrowing as of Mar'21 from ~11.6% as of Dec'20. The cost of excess liquidity was Rs6.84bn for FY21.
- Management is confident of delivering its long-term guidance of AUM growth of 25-27% and RoE target of 18-20% in FY22.

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Net interest income	1,69,124	1,72,691	2,00,026	2,56,335	3,27,922
Other income	34,152	34,152	27,238	31,439	39,291
Net income	2,03,277	2,06,843	2,27,264	2,87,774	3,67,213
Operating expenses	56,608	53,084	69,009	87,104	1,07,404
Pre provision profit	1,46,669	1,53,759	1,58,255	2,00,670	2,59,809
PPP excl treasury	1,46,669	1,53,759	1,58,255	2,00,670	2,59,809
Provisions	31,295	59,686	34,413	34,872	39,399
Profit before tax	1,15,374	94,073	1,23,842	1,65,798	2,20,410
Tax	20,584	15,724	24,441	33,993	45,823
Tax rate	18	17	20	21	21
Profit after tax	94,790	78,349	99,401	1,31,805	1,74,587

Balance Sheet

Y/E Year End (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity	1,200	1,203	1,203	1,203	1,203
Reserves	3,22,076	3,67,981	4,29,517	5,15,102	6,30,474
Net worth	3,23,276	3,69,184	4,30,720	5,16,305	6,31,677
Borrowings	12,98,064	13,16,454	17,03,447	21,80,412	28,34,536
Total liabilities	16,43,914	17,15,269	21,82,636	27,66,865	35,67,691
Cash and bank	13,827	21,762	26,775	23,268	22,600
Investments	1,75,472	1,84,002	2,04,414	2,39,845	2,83,454
Loans	14,31,874	14,83,313	19,14,097	24,50,471	31,85,613
Others	9,564	12,557	17,580	24,612	34,457
Total assets	16,43,914	17,15,269	21,82,636	27,66,865	35,67,691

Key Ratios (%)

Y/E Year End	FY20	FY21	FY22E	FY23E	FY24E
NIM	12.9	11.5	11.6	11.8	11.7
RoA	4.2	2.6	3.7	4.1	4.3
RoAE	23.3	12.8	18.0	21.2	23.6
GNPA (%)	2.1	3.9	3.4	2.3	2.1
NNPA (%)	0.6	1.0	0.9	0.6	0.5

Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	102.6	72.1	117.8	163.8	220.8
BVPS	547.0	602.5	702.9	842.6	1,030.9
ABVPS	536.6	584.9	683.1	825.6	1,010.9
DPS	10.0	10.0	17.7	24.6	33.1

Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	47.4	67.5	41.3	29.7	22.0
P/BV	9.1	8.3	7.1	5.9	4.8
P/ABV	8.9	8.2	7.0	5.8	4.7
Dividend Yield (%)	0.2	0.2	0.4	0.5	0.7
Source: Company, Emkay Research					

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
NII	42.4	2.1	15.8	28.2	27.9
PPOP	49.2	4.8	2.9	26.8	29.5
PAT	54.2	(17.3)	26.9	32.6	32.5
Loans	25.8	3.6	29.0	28.0	30.0

Quarterly (Rs mn)	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
NII	46,834	41,521	41,652	42,958	46,594
NIM (%)	12.8	11.6	12.1	12.2	12.6
PPOP	32,320	29,954	30,059	29,062	30,534
PAT	9,481	9,623	9,649	11,460	13,466
EPS (Rs)	15.80	16.04	16.06	19.07	22.38

Source: Company, Emkay Research

Shareholding Pattern (%)	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21
Promoters	56.2	56.2	56.1	56.1	56.1
FIIs	21.2	21.2	21.3	23.9	24.1
DIIs	10.9	10.1	10.7	9.1	9.1
Public and Others	11.8	12.4	11.9	10.9	10.7

Source: Capitaline

RECOMMENDATION HISTORY TABLE

RECOMMENDAT	Closing		Period	D. ("	A 1 4
Date	Price	TP	(months)	Rating	Analyst
05-Apr-21	4,963	5,400	12m	Hold	Jignesh Shial
19-Feb-21	5,498	5,400	12m	Hold	Jignesh Shial
25-Jan-21	4,909	5,400	12m	Hold	Jignesh Shial
21-Jan-21	5,118	5,200	12m	Hold	Jignesh Shial
21-Oct-20	3,233	2,950	12m	Hold	Jignesh Shial
06-Oct-20	3,474	2,950	12m	Hold	Jignesh Shial
16-Sep-20	3,522	2,950	12m	Hold	Jignesh Shial
22-Jul-20	3,253	2,950	12m	hold	jignesh shial
06-Jul-20	3,109	2,150	12m	Hold	Jignesh Shial
16-Jun-20	2,365	2,150	12m	Hold	Jignesh Shial
20-May-20	2,043	2,150	12m	Hold	Jignesh Shial
14-May-20	2,112	2,331	12m	Hold	Jignesh Shial
05-May-20	2,002	2,331	12m	Hold	Jignesh Shial
19-Apr-20	2,308	2,331	12m	Hold	Jignesh Shial
11-Apr-20	2,552	2,331	12m	Hold	Jignesh Shial
07-Apr-20	2,253	2,331	12m	Hold	Jignesh Shial
05-Apr-20	2,208	3,137	12m	Buy	Jignesh Shial
01-Apr-20	2,219	3,570	12m	Buy	Jignesh Shial
30-Mar-20	2,242	3,570	12m	Buy	Jignesh Shial
24-Mar-20	2,474	3,570	12m	Buy	Jignesh Shial
08-Mar-20	4,226	4,900	12m	Buy	Jignesh Shial
29-Jan-20	4,409	4,900	12m	Buy	Jignesh Shial
06-Jan-20	3,988	4,692	12m	Buy	Jignesh Shial
19-Nov-19	4,126	4,692	12m	Buy	Jignesh Shial
08-Nov-19	4,150	4,692	12m	Buy	Jignesh Shial
22-Oct-19	4,025	4,692	12m	Buy	Jignesh Shial
07-Oct-19	3,892	4,550	12m	Buy	Jignesh Shial
25-Sep-19	3,922	4,550	12m	Buy	Jignesh Shial
28-Aug-19	3,319	4,200	12m	Buy	Jignesh Shial
26-Jul-19	3,257	4,200	12m	Buy	Jignesh Shial
03-Jul-19	3,700	4,200	12m	Buy	Jignesh Shial
25-May-19	3,454	3,665	12m	Buy	Jignesh Shial
16-May-19	3,097	3,665	12m	Buy	Jignesh Shial
18-Apr-19	3,002	3,618	12m	Buy	Jignesh Shial
23-Mar-19	2,825	4,550	12m	Buy	Jignesh Shial
15-Feb-19	2,551	2,971	12m	Buy	Jignesh Shial
29-Jan-19	2,505	2,971	12m	Buy	Jignesh Shial
23-Oct-18	2,075	2,690	12m	Buy	Jignesh Shial
19-Oct-18	2,132	2,785	12m	Buy	Jignesh Shial
26-Sep-18	2,306	2,785	12m	Buy	Jignesh Shial
24-Sep-18	2,252	2,785	12m	Buy	Jignesh Shial
19-Jul-18	2,510	2,785	12m	Buy	Jignesh Shial
29-May-18	2,065	2,375	12m	Buy	Jignesh Shial
17-May-18	2,055	2,375	12m	Buy	Jignesh Shial

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

0

2

0.00

4.08

0.00

Emkay Alpha Portfolio - BFSI-NBFCs



Analyst: Jignesh Shial

Contact Details

jignesh.shial@emkayglobal.com +91 22 6624 2468

Sector

NBFCs/AFCs

Analyst bio

Jignesh Shial is a CA and has total 12 years of research experience. His team currently covers 11 NBFCs/AFCs.

Company Name	Weight	Weight	(%)	(bps)	(Normalised)
BFSI-NBFCs	8.00	8.00	0%	0	100.00
Bajaj Finance	1.53	1.53	0%	0	19.07
Cholamandalam Investment	0.27	0.29	9%	2	3.61
Edelweiss Financial Services	0.00	0.00	NA	0	0.00
HDFC	5.48	5.49	0%	1	68.70
L&T Finance Holdings	0.09	0.10	10%	1	1.20
LIC Housing Finance	0.14	0.15	7%	1	1.92
Magma Fincorp	0.00	0.00	NA	0	0.00
Mahindra Finance	0.13	0.05	-58%	-7	0.67
Nippon Life	0.06	0.06	0%	0	0.73

0.00

0.33

0.00

NA

7%

NA

0.00

0.30

0.00

Source: Emkay Research

Shriram City Union Finance

Shriram Transport Finance

Cash

EAP sector portfolio

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

Sector portfolio NAV

	Base					Latest
	1-Apr-19	23-Apr-20	22-Oct-20	21-Jan-21	22-Mar-21	22-Apr-21
EAP - BFSI-NBFCs	100.0	80.2	101.6	138.9	137.8	131.1
BSE200 Neutral Weighted Portfolio (ETF)	100.0	75.2	95.4	130.6	129.6	123.2


^{*}Performance measurement base date 1st April 2019 Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - BFSI-NBFCs	-4.8%	-5.6%	29.1%	63.4%
BSE200 Neutral Weighted Portfolio (ETF)	-5.0%	-5.6%	29.2%	63.8%

Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio - SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

^{*} Not under coverage: Equal Weight

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 28 Apr 2021 02:59:39 (SGT) Dissemination Date: 28 Apr 2021 03:00:39 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of April 27, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of April 27, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the April 27, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the April 27, 2021

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

RESTRICTIONS ON DISTRIBUTION

12011110110110	701112011011
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
United Kingdom	In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com